COVID-19: Dialysis Machine Makers Respond To Surge In Demand
Baxter and Fresenius are taking extraordinary steps to respond to the flood of COVID-19 patients requiring continuous renal replacement therapy.
You may also be interested in...
The COVID-19 pandemic has increased demand for products from all of Baxter’s businesses except its advanced surgery division. Overall, the diversified company’s global sales were up 8% in the first quarter.
Market Intel: Large Providers Focus On Hemodialysis Home Care; New Incentive By Presidential Executive Order
Momentum is rising for patients with chronic kidney disease to be treated with hemodialysis in the comfort of their own home as opposed to traveling several days a week to a freestanding clinic. Manufacturers, government and payers are paving the way for a higher home-therapy adoption rate. That said, many patients remain unsuitable for home care and the large volume of water needed to operate hemodialysis can be logistically daunting.
Reuters reported that global private equity firm Carlyle Group has offered to pay at least $7bn for Medtronic’s patient monitoring and respiratory interventions businesses. Medtronic announced its plan to get out of those businesses about one year ago.